Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-004728
Filing Date
2025-08-13
Accepted
2025-08-13 20:21:30
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9860
2 d11960522_ex99-a.htm EX-99 4154
3 d11960522_ex99-b.htm EX-99 806
  Complete submission text file 0000919574-25-004728.txt   16594
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Subject) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90878 | Film No.: 251213756
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)